Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Monday, September 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Prelude Therapeutics has announced the publication of an abstract that will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2024. This event is significant for the company as it showcases their research and developments in oncology. The presentation is expected to attract attention from industry professionals and stakeholders.
Price reaction · baseline $4.9 (2024-09-09 open) · hit during market hours · clean, no other PRLD news in the window
day 0 close · peak
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Prelude Therapeutics is actively participating in the ESMO Congress 2024.
  • The publication of the abstract highlights their ongoing research efforts.
  • This engagement may enhance their visibility in the oncology community.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions

Frequently Asked Questions

What is the significance of the ESMO Congress 2024?

The ESMO Congress 2024 is a major event for oncology professionals, showcasing the latest research.

What will Prelude Therapeutics present at ESMO 2024?

Prelude Therapeutics will present an abstract highlighting their research efforts in oncology.

How does this presentation benefit Prelude Therapeutics?

The presentation may enhance Prelude's visibility and credibility within the oncology community.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare Prelude Therapeutics ESMO Congress 2024 oncology abstract publication
Last updated: Sep 9, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →